Open Interest and Volume Dynamics
The latest data reveals that Zydus Lifesciences Ltd’s open interest (OI) in derivatives rose sharply by 2,847 contracts, a 16.89% increase from the previous tally of 16,856 to 19,703. This notable expansion in OI was accompanied by a futures volume of 14,101 contracts, underscoring active trading interest. The combined futures and options value stands at approximately ₹14,972.82 lakhs, with futures alone accounting for ₹12,289.55 lakhs, reflecting substantial liquidity and market depth.
The underlying stock price has also been on an upward trajectory, hitting a new 52-week high of ₹1,181.5 on 8 Jul 2026, marking a 2.47% intraday gain. This price movement outperformed the pharmaceuticals sector by 1.44% and the broader Sensex, which declined by 0.71% on the same day. Over the past four consecutive sessions, Zydus Lifesciences has delivered a cumulative return of 7.1%, signalling sustained bullish momentum.
Technical and Market Positioning Insights
From a technical standpoint, the stock is trading comfortably above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong uptrend and positive investor sentiment. The rising delivery volume, which surged by 49.31% to 11.76 lakh shares on 7 Jul 2026 compared to the five-day average, further confirms increasing investor participation and conviction in the stock’s prospects.
This combination of rising open interest and volume typically suggests fresh long positions being established rather than short covering. Market participants appear to be positioning for further upside, supported by the stock’s liquidity profile that comfortably accommodates trade sizes up to ₹3.53 crore based on 2% of the five-day average traded value.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Mojo Score Upgrade and Market Capitalisation
Zydus Lifesciences Ltd’s recent upgrade in its Mojo Grade from Buy to Strong Buy on 6 Jul 2026 reflects improved fundamentals and technical outlook. The company holds a robust Mojo Score of 80.0, signalling strong buy-side interest and favourable risk-reward dynamics. As a mid-cap pharmaceutical and biotechnology player with a market capitalisation of ₹1,15,002 crore, it occupies a significant position within its sector, attracting both institutional and retail investors.
The stock’s outperformance relative to its sector and the broader market, combined with the surge in open interest, suggests that market participants are increasingly confident in its growth trajectory. This is likely driven by expectations of strong earnings growth, product pipeline developments, and favourable industry tailwinds.
Directional Bets and Derivatives Positioning
The sharp increase in open interest alongside rising futures volume points to a build-up of bullish directional bets. Traders and investors appear to be taking advantage of the stock’s technical strength and positive momentum to establish long positions in the derivatives market. The elevated futures value of ₹12,289.55 lakhs indicates significant capital deployment, which often precedes sustained price moves.
Options market data, with an options value exceeding ₹14,046 crore, also suggests active hedging and speculative activity. The interplay between futures and options volumes can provide insights into market sentiment, with the current scenario indicating a tilt towards optimism and potential upside.
Want to dive deeper on Zydus Lifesciences Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Implications for Investors and Market Outlook
For investors, the surge in open interest and volume in Zydus Lifesciences derivatives signals a compelling opportunity to capitalise on the stock’s bullish momentum. The strong technical positioning, coupled with a positive upgrade in the Mojo Grade, supports a constructive outlook over the near to medium term.
However, investors should remain mindful of broader market volatility and sector-specific risks, including regulatory developments and competitive pressures within the pharmaceuticals and biotechnology space. Continuous monitoring of open interest trends and price action will be crucial to gauge the sustainability of the current rally.
Overall, the data points to a market consensus favouring further appreciation in Zydus Lifesciences Ltd, with increased investor participation and strategic positioning in derivatives underscoring confidence in the stock’s growth prospects.
Summary
Zydus Lifesciences Ltd’s recent open interest surge of 16.89%, combined with rising futures volume and a new 52-week high price, highlights a strong bullish sentiment among market participants. The upgrade to a Strong Buy Mojo Grade and robust delivery volumes reinforce the positive outlook. Derivatives market activity suggests fresh long positions and directional bets, positioning the stock for potential further gains amid favourable sector dynamics and solid fundamentals.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
